Aditxt has submitted more than one request to FDA for Emergency Use Authorization for AditxtScore™ for COVID-19 Tests. These tests are unique as they Measure the Quantity and Quality of Antibodies Against COVID-19 individuals have developed. It’s designed to identify Covid-19 and its Variants Including Omicron. Aditxt follows the guidelines imposed by the US FDA regarding timelines for laboratory-developed tests (“LDT”s), they have requested Emergency Use Authorization (“EUA”) by January 14 2022.
GET A FREE STOCK REPORT
Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.